新型中央孔型ICL V4c植入术治疗高度近视

目的：观察高度近视患者植入新型中央孔型ICL V4c术后中长期疗效及安全性。

方法：选取2016-01/2017-06在我院接受新型中央孔型ICL V4c植入术的高度近视患者58例116眼，术后1wk，1mo，1a进行随访，观察UCVA、BCVA、等效球镜、眼压、角膜内皮细胞计数、拱高、术后不良反应及并发症。

结果：术后UCVA和BCVA较术前提高(P<0.01)，术后1mo与术后1a无差异(P>0.05)，其余术后各时间点两两比较均有差异(P<0.05)。术后SE较术前降低(P<0.01)，虽各时间点两两比较均有差异(P<0.01)，但术后1mo与术后1a等效球镜几乎接近0D。术后1a手术安全指数为1.33±0.67，手术有效性为1.32±0.69。术后各时间点与术前眼压无差异(P>0.05)。术后1a角膜内皮细胞密度与术前无差异(P>0.05)。所有研究对象均未见白内障、青光眼、角膜内皮失代偿等。术后满意度为100%。

结论：新型中央孔型ICL V4c植入术是治疗高度近视安全而有效的方法，术后1mo视力稳定。

Medium and long term observation of ICL V4c implantation for correction of high myopia

AIM: To observe the efficacy and safety of central hole phakic posterior chamber intraocular lens(ICL V4c)implantation for correction high myopia.

METHODS: Fifty-eight high myopia patients(116 eyes)who underwent the ICL V4c implantation in our hospital from January 2016 to June 2017 were observed 1wk, 1mo and 1a after operation respectively. Uncorrected visual acuity(UCVA), best corrected visual acuity(BCVA), equivalent spherical mirrors(SE), intraocular pressure(IOP), corneal endothelial cell count, ICL-vault, adverse reaction and complication were investigated.

RESULTS: Postoperative UCVA and BCVA were significantly higher than that in preoperative group(P<0.01). Significant differences were found between postoperative groups except between 1mo and 1a(P>0.05). Postoperative SE at all time points were lower than that in preoperative group(P<0.01). SE at 1mo and 1a after operation were close to 0 diopter. The safety index in 1a postoperative was 1.33±0.67 and the effective index was 1.32±0.69. No significant differences were found in IOP and endothelial cell density after surgery comparing to that in preoperative group(P>0.05). None of subjects developed cataract, glaucoma and decompensation of corneal endothelium. The degree of postoperative satisfaction was 100%.

CONCLUSION: ICL V4c implantation is a safe and effective method for correction of high myopia. The visual acuity stabilized 1mo after operation.